Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, P. G.
Right arrow Articles by Ambinder, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, P. G.
Right arrow Articles by Ambinder, R. F.
Related Collections
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 92 No. 7 (October 1), 1998: pp. 2477-2483

Analysis of Major Histocompatibility Complex Class I, TAP Expression, and LMP2 Epitope Sequence in Epstein-Barr Virus-Positive Hodgkin's Disease

By Paul G. Murray, Christothea M. Constandinou, John Crocker, Lawrence S. Young, and Richard F. Ambinder

From the CRC Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham; the School of Health Sciences, University of Wolverhampton, Wolverhampton; the Department of Histopathology, Birmingham Heartland Hospital, Birmingham, UK; and Johns Hopkins Oncology Center, Baltimore, MD.


    ABSTRACT
Abstract
Introduction
Methods
Results
Discussion
References

The Epstein-Barr virus (EBV)-encoded latent membrane proteins, LMP1 and LMP2, are consistently expressed by the malignant Hodgkin/Reed-Sternberg (HRS) cells of EBV-associated Hodgkin's disease (HD). Cytotoxic T lymphocyte (CTL) responses to both of these proteins have been shown in the blood of EBV-seropositive individuals, yet in HD the apparent failure of the CTL response to eliminate HRS cells expressing LMP1 and LMP2 in vivo has given rise to the suggestion that HD may be characterized by the presence of defects in antigen processing/presentation or in CTL function. This study has used immunohistochemistry to show high-level expression of major histocompatibility complex (MHC) class I molecules by the HRS cells of EBV-associated HD and either low level or absence of expression of MHC class I molecules on HRS cells of EBV-negative tumors. In addition, HRS cells expressed high levels of transporter-associated proteins (TAP-1, -2), irrespective of the presence of latent EBV infection. These results suggest that global downregulation of MHC class I molecules does not account for the apparent ability of EBV-infected HRS cells to evade CTL responses, but may be important in the understanding of EBV-negative disease.We have also sequenced an epitope in LMP2A (CLGGLLTMV) that is restricted through HLA A2.1, a relatively common allele in Caucasian populations, and showed that this epitope is wild type in a small group of EBV-associated HLA A2.1-positive HD tumors. This result may be relevant to proposed immunotherapeutic approaches for EBV-positive HD patients that target CTL epitopes.

    INTRODUCTION
Abstract
Introduction
Methods
Results
Discussion
References

THE EPSTEIN-BARR VIRUS (EBV) is a human herpesvirus that infects approximately 95% of the world's adult population.1 EBV is generally carried as a clinically silent infection but is strongly implicated in the pathogenesis of a number of human malignancies including African Burkitt's lymphoma,2,3 nasopharyngeal carcinoma,4,5 and more recently, Hodgkin's disease (HD). EBV DNA has been detected in the tumor samples of HD patients by Southern blotting and polymerase chain reaction (PCR) analysis6-9 and a variety of studies have localized viral DNA10 and virus gene products11-13 to the malignant Hodgkin/Reed-Sternberg (HRS) cells of HD. Furthermore, using EBV terminal repeat probes, the EBV genomes within individual cases have been shown to be monoclonal in origin, suggesting that monoclonal proliferation occurred after EBV infection.7,8,10,14 The frequent occurrence of abnormally elevated titers of antibodies against EBV antigens before the onset of overt disease and the detection of impaired cellular responses to EBV in HD patients have led to the hypothesis that a defective control of EBV-infected cells might be important in the pathogenesis of a proportion of HD tumors.15-19 EBV-infected HRS cells are characterized by a pattern of viral protein expression that is restricted to EBNA1, LMP1, and LMP2.12,20-23 Although the dominant CTL responses seem to be directed to epitopes in proteins of the EBNA3 family, LMP1 and LMP2 have been shown to be targets for autologous cytotoxic T lymphocytes (CTLs) in vitro.24-27 The apparent failure of the immune system to eliminate HRS cells expressing potential targets for CTLs has provided further support for immunologic dysfunction in EBV-associated HD.

One possible mechanism of CTL escape in EBV-associated HD may be downregulation of major histocompatibility complex (MHC) class I molecules on HRS cells. CTLs recognize endogenously processed virus proteins only when presented at the cell surface as peptides bound to MHC class I molecules. A reduction or the absence of MHC class I expression can therefore render virus-infected cells resistant to CTL destruction. Such a mechanism has been shown previously for some virus-associated tumors, including EBV-associated Burkitt's lymphoma (BL) and a proportion of human papilloma virus (HPV)-infected cervical carcinomas.28-31 In the case of HPV-positive cervical carcinomas, MHC class I downregulation was associated with the loss of function of one of the transporter-associated proteins (TAP-1).32,33

It has been shown that amino acid substitutions at key positions within peptides presented by MHC class I molecules may reduce or completely abrogate CTL responses. For example, two HLA A11-restricted CTL epitopes (residues 399-408 and 416-424) from the EBNA3B protein are regularly mutated in EBV strains from Southeast Asia,34,35 and memory CTL responses specific for the variant epitopes have not been detectable in HLA A11-positive Chinese donors infected with the mutated viruses. It is possible that similar mechanisms might also account for the failure of CTLs to eliminate EBV-infected HRS cells.

Therefore, the aim of this current study was to investigate the expression of MHC class I and TAP molecules in both EBV-positive and EBV-negative HD. The identification of an epitope in LMP2 (CLGGLLTMV) that is restricted through HLA A2.1, a relatively common allele in Caucasian populations, provides an ideal target to study the possibility that epitope variations in EBV genes expressed in tumor tissues might be responsible for CTL escape.36

    MATERIALS AND METHODS
Abstract
Introduction
Methods
Results
Discussion
References

Preparation of specimens.   Paraffin-wax sections and paraffin-wax-embedded tissue blocks from 39 cases of HD were available from the pathology files of the Johns Hopkins Hospital, Baltimore, MD; and the Queen Elizabeth Hospital, Birmingham, UK. From tissue blocks 4-µm paraffin sections were prepared and all sections were deparaffinized and washed in Tris-buffered saline (TBS), pH 7.6. Cryostat sections were also prepared from selected samples. Hematoxylin and eosin-stained sections of HD tumors were reviewed and subtyped according to the Rye classification system.

Detection of latent EBV infection.   In situ hybridization for the detection of the Epstein-Barr virus early RNAs (EBERs) was performed according to standard methods.37 Positive controls for EBER in situ hybridization included paraffin-wax sections of lymphoblastoid cell lines (LCL) grown as solid tumors in severe combined immunodeficiency (SCID) mice (LCL-SCID tumors) and a known EBER-positive HD case. U6 and sense control probes were included in all runs.

Immunohistology.   Immunohistochemistry for LMP1 and LMP2 was also performed on selected cases to confirm the presence of latent EBV infection in HRS cells. Immunostaining for MHC class I and TAP-1 was performed on acetone-fixed frozen and paraffin-wax sections of HD tissues and on a variety of cell lines (Table 1), including the HD lines HDLM2, L428, HS445, and Km-H2. HD cell lines and selected HD biopsies were also stained for TAP-2. Immunohistochemistry for TAP-1 and TAP-2 was additionally performed on acetone-fixed cytospin preparations of the BL lines, Mutu I (group I BL) and Mutu III (group III BL).

 
View this table:
[in this window] [in a new window]
  		Table 1. Cell Lines Used in the Study

The demonstration of some antigens in paraffin material required microwave pretreatment in 0.1 mol/L citrate buffer, pH 6.0. The optimum microwave pretreatment times were determined for each antigen and are listed in Table 2. After pretreatment, endogenous peroxidase activity was blocked in 0.3% hydrogen peroxide in methanol and sections transferred to TBS.

 
View this table:
[in this window] [in a new window]
  		Table 2. Primary Antibodies Used in the Immunohistochemical Analyses, Together With Optimum Dilutions and Microwave Pretreatment Times

Sections were then incubated in primary antibodies at optimum dilutions previously determined for each antibody (Table 2). All primary antibodies were diluted in 10% normal sheep serum. Mouse monoclonal antibodies were detected either using the peroxidase-based Dako Duet system (Dako Ltd cat no: K492; Dako Ltd, Glostrup, Denmark) or the standard alkaline phosphatase and alkaline phosphatase (APAAP) method. The rat monoclonal antibody to LMP2 was detected using rabbit anti-rat immunoglobulins (Dako Ltd cat no: Z455) at a dilution of 1:400, followed by the Dako Catalyzed Signal Amplification system (Dako Ltd cat no:K0620).

Positive controls for LMP1 and LMP2 immunostaining consisted of paraffin-wax sections of LCL-SCID tumors. Positive controls for MHC class I, TAP-1, and TAP-2 included paraffin-wax and frozen sections of human tonsil. Negative controls for immunohistochemistry consisted of consecutive test sections in which the primary antibody was replaced with nonimmune serum of the same IgG subclass. Full details of antibodies used are given in Table 2.

Epitope sequencing.   A series of frozen HD biopsies were initially studied to determine their EBV and MHC status. The presence of latent EBV infection was determined as described above. HLA A2.1-positive tumor samples were identified in APAAP immunohistochemical assays using the MA2.1 antibody (Table 2). A variety of HLA A2.1-positive cell lines (both homozygous and heterozygous) and HLA A2.1-negative cell lines (Table 1) were used as controls in these immunohistochemical assays. Both acetone-fixed cytospin preparations and frozen sections of SCID tumors generated from these lines were tested.

HLA A2.1 and EBV-positive HD samples identified in this way were subjected to DNA extraction and PCR sequencing to determine the sequence of the LMP2A epitope, CLGGLLTMV, previously identified to be restricted through HLA A2.1. Sequences were compared with wild-type (B95.8) DNA. To obtain sufficient DNA from HD biopsies for sequencing it was necessary to extract DNA from agarose gels for reamplification. Primers, D5639LY and D5640LY (Fig 1A), were used in both PCR amplification and sequencing steps. Sequencing was performed twice in both directions on all samples.


View larger version (19K):
[in this window]
[in a new window]
  		Fig 1. (A) LMP2A sequence showing position of epitope and primers used in the PCR and sequencing analyses. (B) Autoradiograph of sequencing gel showing wild-type LMP2 sequence.

    RESULTS
Abstract
Introduction
Methods
Results
Discussion
References

Detection of latent EBV gene expression.   EBER expression was shown in HRS cells of 18 of 39 examined HD cases. The expression of LMP1 in all EBER-positive HD cases was confirmed by immunohistochemistry. LMP2 protein was also detectable in the cytoplasm of HRS cells in 16 of 16 EBV-positive HD cases (Fig 2).


View larger version (163K):
[in this window]
[in a new window]
  		Fig 2. Immunohistochemical demonstration of LMP2 expression by HRS cells in a case of EBV-positive HD.

MHC class I staining.   In all tissue sections, the presence of MHC class I-positive cells served as an internal control. Expression of MHC class I was mainly confined to the cell membrane of positively stained cells. Of 17 cases of EBER-positive HD analyzed, 13 showed the presence of MHC class I expression on HRS cells. However, MHC class I expression was detectable on HRS cells in only 4 of 21 cases of EBV-negative HD. In most EBV-positive HD samples, HRS cells could be easily identified because the intensity of class I staining was often stronger than on surrounding reactive cells (Fig 3A). This was in contrast to the majority of EBV-negative HD tumors, where HRS cells were either not stained or only weakly stained for class I (Fig 3B). Class I expression was not related to subtype, and similar results were obtained on paraffin and frozen sections of HD tumors. In all cases, reactivity of surrounding reactive cells could be distinguished from staining on HRS cells. The HD cell lines, HDLM2, Km-H2, and HS445, all showed strong expression of MHC class I, whereas the HD cell line, L428, was consistently negative in all assays (not shown).


View larger version (74K):
[in this window]
[in a new window]
  		Fig 3. Immunohistochemistry for MHC class I expression. Long black arrows show class I expression on HRS cells (A) or its absence (B). The intensity of class I staining on surrounding small reactive cells (short red arrows) is less than that of the HRS cells in (A) and greater than that of the HRS cells in (B).

Immunohistochemistry for TAP-1 and TAP-2.   On control tonsil tissue, germinal center cells were generally not stained for TAP-1 and TAP-2, with the exception of occasional positive cells. The interfollicular cells were most strongly stained for both markers and the squamous epithelium, when present, was also positively stained (data not shown). Similar results were obtained on both frozen and paraffin-wax sections. Cell preparations (both acetone-fixed cytospins and pelleted paraffin-wax sections) of Mutu I and Mutu III cell lines expressed both TAP-1 and TAP-2, although staining for both markers was noticeably weaker in Mutu I cells when compared with the Mutu III line. All the HD cell lines tested (HDLM2, L428, HS445, and Km-H2) were strongly stained for both TAP-1 and TAP-2. Frozen and paraffin wax-embedded HD tumors were also analyzed for TAP-1 and TAP-2 expression. With the exception of two HD cases, HRS cells showed strong staining for TAP-1 (Fig 4), irrespective of the presence of latent EBV infection in these cells. Selected HD cases were also stained for TAP-2. In all cases, HRS cells showed strong staining for TAP-2 (not shown).The results of EBER in situ hybridization, MHC I, and TAP-1 immunohistochemical assays are summarized in Table 3.


View larger version (152K):
[in this window]
[in a new window]
  		Fig 4. Immunohistochemistry for TAP-1 in HD by HRS cells.

 
View this table:
[in this window] [in a new window]
  		Table 3. Expression of MHC Class I and TAP-1 by HRS Cells in HD Specimens: Correlation With the Presence of EBV Within HRS Cells as Determined by EBER In Situ Hybridization (EBERs) and Subtype

Epitope sequencing.   A series of LCLs prepared from HLA A2.1-positive and -negative donors (Table 1) initially served as controls for the MA2.1 antibody. All cell lines from A2.1-positive donors reacted strongly with this antibody in APAAP assays, and all A2.1-negative cell lines, as expected, were nonreactive (data not shown).

Of the 20 HD biopsies available as frozen material, 9 contained EBER-positive HRS cells, and a further 6 of these were HLA A2.1 positive by immunohistochemistry. These 6 biopsies were subjected to PCR analysis to determine the sequence of the A2.1-restricted LMP2A-derived CTL epitope, CLGGLLMTV (Fig 1B). All 6 HD tumors showed wild-type epitope sequence.

    DISCUSSION
Abstract
Introduction
Methods
Results
Discussion
References

There are strong indications that the outgrowth of EBV-infected tumors in vivo is dependent on the pattern of viral antigens expressed by the tumor and also the level of immunocompetence of the host. For example, the role of immunosurveillance in limiting the proliferation of EBV-infected cells in vivo is clearly illustrated by the development of EBV-positive lymphoproliferative disease in immunocompromised individuals.38-41 These lymphoproliferations may be regarded as the in vivo counterpart of LCLs. Indeed, these lesions often regress when immunosuppressive therapy is withdrawn or reduced.42,43 Many of these lesions express the full spectrum of EBV latent genes, with high cell surface expression of ICAM1 and LFA3 providing a wide range of potential targets for the immune system.44 It generally has been assumed that the sensitivity of these lesions to EBV-specific CTLs may be similar to LCLs. Evidence supporting this assumption has recently been provided by adoptive transfer experiments in which donor lymphocytes were used as a source of virus-specific CTLs to treat EBV lymphoproliferative disease in bone marrow transplant recipients.45,46

In contrast to posttransplant lymphoproliferative disease and related conditions, HD arises in relatively immunocompetent hosts. The consistent expression of LMP1 and LMP2 in EBV-positive HD3,12,20,21 and the demonstration of effective CTL responses to epitopes derived from these proteins in vitro36,47,48 implies that defects in the antigen processing/recognition machinery may be a feature of these tumors. The mechanisms accounting for the failure of CTLs to eliminate EBV-infected HRS cells have not been established yet, although MHC class I downregulation by HRS cells, as originally demonstrated by Poppema and Visser,49 has been suggested as a possible mechanism.

This study has shown high-level expression of MHC class I molecules on the surface of HRS cells in EBV-associated HD cases, and much lower levels of expression or the absence of expression on HRS cells in EBV-negative samples, and is in accordance with the results of a previous study.50 These results suggest that MHC class I downregulation is unlikely to account for the failure of CTLs to eliminate the tumor cells, at least in EBV-positive cases. The mechanism responsible for downregulation or absence of MHC molecules in EBV-negative HD has yet to be determined. Unlike cervical carcinomas, where downregulation of MHC class I was associated with low-level expression of TAP molecules,32 downregulation of TAP molecules was not shown in this present study. The high-level expression of MHC class I molecules on EBV-positive HRS cells potentially could be mediated by LMP1 expression. LMP1 has been shown to upregulate class I expression when transfected into EBV-negative B-cell lines51 and epithelial cells (Dawson C. and L.S.Y., unpublished observations). LMP1 also has been shown to increase the stimulatory capacity of EBV-negative BL lines in allogeneic mixed lymphocyte cultures,51 to upregulate the expression of adhesion molecules,52 and to enhance the presentation of endogenous and exogenous antigens.53,54

Another possible mechanism of CTL escape is suggested by the finding that memory CTL responses specific for variant epitopes in two HLA A11-restricted CTL epitopes (residues 399-408 and 416-424) from the EBNA3B protein were not detectable in HLA A11-positive Chinese donors infected with strain variants.34,35 This present study has established that a recently identified epitope in LMP2 that is restricted through HLA A2.155 is wild type in a small series of HLA A2-positive HD tumors, suggesting that mutation in virus epitope sequences may not be a common feature of EBV-positive HD, at least in this group of patients. Similar data showing that this same epitope is not commonly mutated has been presented by Bryden et al.56 The lack of mutation may have important implications for potential CTL therapy for HD patients, particularly because the CTL response to this epitope previously has been shown to be reactive against a range of virus isolates, including type-1 and type-2 Caucasian, Southeast Asian, New Guinean, and African isolates. Some of these isolates contained amino acid substitutions within the epitope, but were nevertheless recognized by CTLs raised against the B95.8 virus.36 The finding of similar, functionally conserved epitopes restricted through relatively common HLA alleles may be important for the future development of CTL therapy for EBV-associated HD.

Recent studies have shown that the HD cell line, HDLM2, is able to process and present epitopes from LMP1 and LMP2 in the context of multiple class I alleles including HLA A2 and is sensitive to lysis by EBV-specific CTLs.48 Furthermore, using autologous fibroblasts infected with a vaccinia recombinant encoding LMP2 as a target, the same authors were able to identify and expand LMP2-specific CTLs from the peripheral blood of an HD patient. However, recent data have pointed to the possibility of local suppression of EBV-specific immunity in the vicinity of the tumor that may confound certain immunotherapeutic strategies in HD. This was first suggested by a comparative study of EBV-specific responses in patients with EBV-positive and EBV-negative HD which failed to show virus-specific cytotoxicity in the tumor-infiltrating lymphocytes of six EBV-positive cases.57 However, CTL precursors were detected in the blood of one of the EBV-positive patients. A possible explanation of this finding was reported by Herbst et al,58 who showed that significantly higher proportions of EBV-positive HD cases contained interleukin-10 (IL-10)-expressing tumor cells when compared with EBV-negative tumors, suggesting that IL-10 production by HRS cells may be responsible for local downregulation of the CTL response in EBV-positive cases.58

The results of this present study provide some encouragement for the pursuit of CTL therapy for EBV-associated HD. However, further work is required to establish if the microenvironment of EBV-positive HRS cells is responsible for the inhibition of virus-specific CTLs and whether this effect is likely to confound immunotherapeutic strategies targeted at EBV-positive HD patients.

    NOTE ADDED IN PROOF

Similar data regarding MHC class I and TAP expression in Hodgkin's disease have recently been presented.67

    FOOTNOTES

   Submitted April 24, 1998; accepted June 2, 1998.
   R.F.A. is a Leukemia Society Scholar.
   Supported by the Cancer Research Campaign and the National Institutes of Health Grants No. PO1 CA15396 and PO1 CA69266.
   Address reprint requests to Richard F. Ambinder, MD, PhD, Johns Hopkins Oncology Center, 418 N Bond St, Baltimore, MD 21231.
   The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" is accordance with 18 U.S.C. section 1734 solely to indicate this fact.

    REFERENCES
Abstract
Introduction
Methods
Results
Discussion
References

1. Miller G: Epstein-Barr virus. Biology, pathogenesis, and medical aspects, in Fields BN, Knipe DM (eds): Virology (ed 2). New York, NY, Raven, 1990, p 1921

2. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF: Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: Molecular analysis of primary tumor tissue. Blood 91:1373, 1998[Abstract/Free Full Text]

3. Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS: Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 86:659, 1995[Abstract/Free Full Text]

4. Wu TC, Mann RB, Epstein J, MacMahon E, Lee WA, Charache P, Hayward SD, Kurman RJ, Hayward GS, Ambinder RF: Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma: A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol 138:1461, 1991[Abstract]

5. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB: Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69:1051, 1988[Abstract/Free Full Text]

6. Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J: Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 129:86, 1987[Abstract]

7. Staal SP, Ambinder R, Beschorner WE, Hayward GS, Mann R: A survey of Epstein-Barr virus DNA in lymphoid tissue: Frequent detection in Hodgkin's disease. Am J Clin Pathol 91:1, 1989[Medline] [Order article via Infotrieve]

8. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H: Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1 positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 74:810, 1989[Abstract/Free Full Text]

9. Gledhill S, Gallagher A, Jones DB, Krajewski AS, Alexander FE, Klee E, Wright DH, O'Brien C, Onions DE, Jarrett RF: Viral involvement in Hodgkin's disease: Detection of clonal type A Epstein-Barr virus genomes in tumour samples. Br J Cancer 64:227, 1991[Medline] [Order article via Infotrieve]

10. Weiss LM, Movahed LA, Warnke RA, Sklar J: Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 320:502, 1989[Abstract]

11. Wu TC, Mann RB, Charache P, Hayward SD, Staal S, Lambe BC, Ambinder RF: Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer 46:801, 1990[Medline] [Order article via Infotrieve]

12. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS: Expression of Epstein-Barr virus (EBV) latent gene products in tumour cells of Hodgkin's disease. Lancet 337:320, 1991[Medline] [Order article via Infotrieve]

13. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller-Lantzsch N, Stein H: Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 88:4766, 1991[Abstract/Free Full Text]

14. Gulley ML, Eagan PA, Quintanilla-Martinez L, Picado AL, Smir BN, Childs C, Dunn CD, Craig FE, Williams JW Jr, Banks PM: Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: Association with mixed cellularity subtype and Hispanic American ethnicity. Blood 83:1595, 1994[Abstract/Free Full Text]

15. Levine PH, Ablashi DV, Berard CW, Carbone PP, Waggoner DE, Malan L: Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer 27:416, 1971[Medline] [Order article via Infotrieve]

16. Henderson BE, Dworsky R, Menck H, Alena B, Henle W, Henle G, Terasaki P, Newell GR, Rawlings W, Kinnear BK: Case-control study of Hodgkin's disease. II. Herpesvirus group antibody titers and HL-A type. J Natl Cancer Inst 51:1443, 1973

17. Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelman J: Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 320:689, 1989[Abstract]

18. Levine PH, Pallesen G, Ebbesen P, Harris N, Evans AS, Mueller N: Evaluation of Epstein-Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin's disease. Int J Cancer 59:48, 1994[Medline] [Order article via Infotrieve]

19. Alexander FE, Daniel CP, Armstrong AA, Clark DA, Onions DE, Cartwright RA, Jarrett RF: Case clustering, Epstein-Barr virus Reed-Sternberg cell status and herpes virus serology in Hodgkin's disease: Results of a case-control study. Eur J Cancer 31A:1479, 1995 (suppl)

20. Murray PG, Young LS, Rowe M, Crocker J: Immunohistochemical diagnosis of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol 166:1, 1992[Medline] [Order article via Infotrieve]

21. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS: Epstein-Barr virus and Hodgkin's disease: Transcriptional analysis of virus latency in the malignant cells. J Exp Med 177:339, 1993[Abstract/Free Full Text]

22. Niedobitek G, Kremmer E, Herbst H, Whitehead L, Dawson CW, Niedobitek E, von Ostau C, Rooney N, Grasser FA, Young LS: Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 90:1664, 1997[Abstract/Free Full Text]

23. Grasser FA, Murray PG, Kremmer E, Klein K, Remberger K, Feiden W, Reynolds G, Niedobitek G, Young LS, Mueller-Lantzsch N: Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): Imunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 84:3792, 1994[Abstract/Free Full Text]

24. Gavioli R, Kurilla MG, De Campos-Lima PO, Wallace LE, Dolcetti R, Murray RJ, Rickinson AB, Masucci MG: Multiple HLA A11-resricted cytotoxic T lymphocyte epitopes of different immunogenicities in the EBV-encoded nuclear antigen 4. J Virol 67:1572, 1993[Abstract/Free Full Text]

25. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwaldmullen PM, Klein G, Kurilla MG, Masucci MG: Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685, 1995[Medline] [Order article via Infotrieve]

26. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ: Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J Exp Med 176:169, 1992[Abstract/Free Full Text]

27. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB: Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176:157, 1992[Abstract/Free Full Text]

28. Imreh MP, Zhang QJ, De Campos-Lima PO, Imreh S, Krausa P, Browning M, Klein G, Masucci MG: Mechanisms of allele-selective down-regulation of HLA class I in Burkitt's lymphoma. Int J Cancer 62:90, 1995[Medline] [Order article via Infotrieve]

29. Masucci MG, Klein E: Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines. Semin Cancer Biol 2:63, 1991[Medline] [Order article via Infotrieve]

30. Cromme FV, van Bommel PF, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ, Meijer CJ: Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 69:1176, 1994[Medline] [Order article via Infotrieve]

31. Cromme FV, Snijders PJ, van den Brule AJ, Kenemans P, Meijer CJ, Walboomers JM: HC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene 8:2969, 1993[Medline] [Order article via Infotrieve]

32. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM: Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335, 1994[Abstract/Free Full Text]

33. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A: Sequences encoded in the class II region of the MHC related to the `ABC' superfamily of transporters. Nature 348:741, 1990[Medline] [Order article via Infotrieve]

34. De Campos-Lima PO, Gavioli R, Zhang QJ, Wallace LE, Dolcetti R, Rowe M, Rickinson AB, Masucci MG: HLA-A11 epitope loss in isolates of Epstein-Barr virus from a highly A11+ population. Science 260:98, 1993[Abstract/Free Full Text]

35. De Campos-Lima PO, Levitsky V, Brooks J, Lee SP, Hu LF, Rickinson AB, Masucci MG: T cell responses and virus evolution: Loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med 179:1297, 1994[Abstract/Free Full Text]

36. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB: Conserved CTL epitopes within EBV latent membrane protein 2: A potential target for CTL-based tumor therapy. J Immunol 158:3325, 1997[Abstract]

37. Barletta JM, Kingma DW, Ling Y, Charache P, Mann RB, Ambinder RF: Rapid in situ hybridization for the diagnosis of latent Epstein-Barr virus infection. Mol Cell Probes 7:105, 1993[Medline] [Order article via Infotrieve]

38. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J: The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133:173, 1988[Abstract]

39. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552, 1995[Abstract/Free Full Text]

40. Filipovich AH, Mertens A, Robison L, Ambinder RF, Shapiro RS, Frizzera G: Lymphoproliferative disorders associated with primary immunofeficiencies, in Magrath I (ed): The Non-Hodgkin's Lymphomas. New York, NY, Oxford, 1995, p 459

41. Hamilton-Dutoit SJ, Rea D, Raphael M, Sandvej K, Delecluse HJ, Gisselbrecht C, Marelle L, van Krieken HJ, Pallesen G: Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 143:1072, 1993[Abstract]

42. Starzl TE, Porter KA, Iwatsuki S, Rosenthal JT, Shaw BW Jr, Atchison RW, Nalesnik MA, Ho M, Griffith BP, Hakala TR, Hardesty RL, Jaffe R, Bahnson HT: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583, 1984[Medline] [Order article via Infotrieve]

43. Crawford DH, Thomas JA, Janossy G, Sweny P, Fernando ON, Moorhead JF, Thompson JH: Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet 1:1355, 1980[Medline] [Order article via Infotrieve]

44. Thomas JA, Hotchin NA, Allday MJ, Amlot P, Rose M, Yacoub M, Crawford DH: Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49:944, 1990[Medline] [Order article via Infotrieve]

45. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O'Reilly RJ: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 33:1185, 1994

46. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9, 1995[Medline] [Order article via Infotrieve]

47. Rickinson AB, Moss DJ: Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15:405, 1997[Medline] [Order article via Infotrieve]

48. Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E, Greenberg PD: Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: Implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 89:1978, 1997[Abstract/Free Full Text]

49. Poppema S, Visser L: Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 145:37, 1994[Abstract]

50. Oudejans JJ, Jiwa NM, Kummer JA, Horstman A, Vos W, Baak JPA, Kluin PM, Vandervalk P, Walboomers JMM, Meijer CJLM: Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkins disease. Blood 87:3844, 1996[Abstract/Free Full Text]

51. Cuomo L, Trivedi P, Wang F, Wimberg G, Klein G, Masucci M: Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen LMP increases the stimulatory capacity of EBV negative B lymphoma lines in allogeneic mixed lymphocyte cultures. Eur J Immunol 20:2293, 1990[Medline] [Order article via Infotrieve]

52. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E: Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64:2309, 1990[Abstract/Free Full Text]

53. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR, Trowsdale J, Moss DJ, Rickinson AB: Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 25:1374, 1995[Medline] [Order article via Infotrieve]

54. De Campos-Lima PO, Torsteindottir S, Cuomo L, Klein G, Sulitzeanu D, Masucci M: Antigen processing and presentation by EBV-carrying cell lines: Cell-phenotype dependence and influence of the EBV-encoded LMP1. Int J Cancer 53:856, 1993[Medline] [Order article via Infotrieve]

55. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB: HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67:7428, 1993[Abstract/Free Full Text]

56. Bryden H, MacKenzie J, Andrew L, Alexander FE, Angus B, Krajewski AS, Armstrong AA, Gray D, Cartwright RA, Kane E, Wright DH, Taylor P, Jarrett RF: Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein. Int J Cancer 72:614, 1997[Medline] [Order article via Infotrieve]

57. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, Brautbar C, Battat S, Biberfeld P, Eckman M, Ost O, Christensson B, Sundstrom C, Bjorkholm M, Pisa P, Masucci MG: Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86:1493, 1995[Abstract/Free Full Text]

58. Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, Krause H, Agathanggelou A, Niedobitek G, Stein H: Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 87:2918, 1996[Abstract/Free Full Text]

59. Miller G, Shope T, Lisco H, Stitt D, Lipman M: Epstein-Barr virus: Transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci USA 69:383, 1972[Abstract/Free Full Text]

60. Yandava CN, Speck SH: Characterization of the deletion and rearrangement in the BamHI C region of the X50-7 Epstein-Barr virus genome, a mutant viral strain which exhibits constitutive BamHI W promoter activity. J Virol 66:5646, 1992[Abstract/Free Full Text]

61. Gregory CD, Rowe M, Rickinson AB: Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 71:1481, 1990[Abstract/Free Full Text]

62. Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, Miwa H, Shirakawa S, Hatanaka M, Honjo T: Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 68:285, 1986[Abstract/Free Full Text]

63. Drexler HG, Gaedicke G, Lok MS, Diehl V, Minowada J: Hodgkin's disease derived cell lines HDLM-2 and L-428: Comparision of morphology, immunological and isoenzyme profiles. Leuk Res 10:487, 1986[Medline] [Order article via Infotrieve]

64. Schaadt M, Diehl V, Stein H, Fonatsch C, Kirchner HH: Two neoplastic cell lines with unique features derived from Hodgkin's disease. Int J Cancer 26:723, 1980[Medline] [Order article via Infotrieve]

65. Klein S, Jucker M, Diehl V, Tesch H: Production of multiple cytokines by Hodgkin's disease derived cell lines. Hematol Oncol 10:319, 1992[Medline] [Order article via Infotrieve]

66. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, Cohen JI: Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321:1080, 1989[Abstract]

67. Lee SP, Constandinou CM, Thomas WA, Croom-Carter D, Blake NW, Murray PG, Crocker J, Rickinson AB: Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: Analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood 92:1020, 1998[Abstract/Free Full Text]

© 1998 by the American Society of Hematology.
 
0006-4971/98/92-0031$3.00/0

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
G Kapatai and P Murray
Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma
J. Clin. Pathol., December 1, 2007; 60(12): 1342 - 1349.
[Abstract] [Full Text] [PDF]